We were delighted to talk to Editor-in-Chief Prof. Axel Merseburger (Professor and Chairman, Department of Urology, University of Lübeck, Lübeck, Germany) around the TITAN trial in metastatic castration-sensitive prostate cancer (ClinicalTrials.gov Identifer: NCT02489318). The abstract “Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT)” (Abstract 11) was presented at the 2021 Genitourinary Cancers Symposium, 11–13 February 2021.
Prof. Axel Merseburger also discusses updates in immunotherapy in genitourinary cancers on our sister site, touchIMMUNOLOGY.
- Could you give us a brief overview of the TITAN phase III study? (00:17)
- What did the final TITAN analysis show in terms of efficacy, safety and health-related quality of life outcomes? (01:21)
- On the basis of these findings, what will be the likely place of apalutamide in combination with androgen deprivation therapy in the treatment paradigm for patients with metastatic castration-sensitive prostate cancer? (2:47)
Disclosures: Prof. Axel Merseburger has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2021 Genitourinary Cancers Symposium (Virtual), 11–13 February 2021.
Chi KN, Chowdhury S, Bjartell A, et al. Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). J Clin Oncol. 2021;39(Suppl.6):11.
Share this Video
Related Videos In Prostate Cancer
ARPi vs. SOC and taxanes in mCRPC – ProBio study: Henrik Grönberg, EMSO 2023
The uniquely designed Prostate Biomarker (ProBio) study (NCT03903835) used outcome-adaptive randomization to compare biomarker-driven treatment selection against physician’s choice, and to compare androgen receptor inhibitors (ARPIs) against standard-of-care (SOC) and taxanes in castrate-resistant prostate cancer (mCRPC). To learn more about the trials unique design, the details surrounding the biomarker signatures investigated and the treatments compared, […]
Arnulf Stenzl: Highlights from EAU23!
touchONCOLOGY caught up with the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the key advances from the conference. He focusses this interview on prostate cancer, early detection, systemic therapy, new therapies in castration-resistant prostate cancer and the latest knowledge in the use of PARP inhibitors. Topics […]
Axel Merseburger: Current advances in prostate cancer treatment options and what we might expect in the next 5 years
Our Editor-in-Chief Axel Merseburger (Lübeck University, Lübeck, Germany) discusses the most important recent advances in the treatment landscape for prostate cancer, including screening using MRI and PSMA PET-CT scans, and triplet therapies using hormone therapy and PARP inhibitors. He also takes a look to the future, discussing developments he hopes to see in early detection, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!